Access to combinations of BRAF, MEK, and other pathway inhibitors is currently not Food and Drug Administration (FDA) approved for the treatment of metastatic BRAF V600E CRC; nevertheless, this off-label strategic implementation deserves consideration based on the growing body of literature. Here, MAP2K7 is linked to colorectal carcinoma.